AIMS: This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl Ester Transfer Protein (E3L.CETP) mice and (ii) whether the response of this model to different antidiabetic and hypolipidemic drugs is similar as in humans. METHODS: Male obese, IR and dyslipidemic E3L.CETP mice were treated with antidiabetic drugs rosiglitazone, liraglutide or an experimental 11β-hydroxysteroid-dehydrogenase-1 (HSD-1) inhibitor, or with hypolipidemic drugs atorvastatin, fenofibrate or niacin for 4-6 weeks. The effects on bw, IR and plasma and liver lipids were assessed. RESULTS: Rosiglitazone, liraglutide and HSD-1 inhibitor significantly decreased glucose and insulin levels or IR. Liraglutide and HSD-1 inhibitor also decreased bw. Atorvastatin, fenofibrate and niacin improved the dyslipidemia and fenofibrate and niacin increased high-density lipoprotein (HDL) cholesterol. In addition, hepatic triglycerides were significantly decreased by treatment with rosiglitazone and liraglutide, while hepatic cholesterol esters were significantly decreased by rosiglitazone and atorvastatin. CONCLUSIONS: We conclude that the E3L.CETP mouse is a promising novel translational model to investigate the effects of new drugs, alone or in combination, that affect IR, diabetic dyslipidemia and non-alcoholic fatty liver disease (NAFLD).
AIMS: This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl Ester Transfer Protein (E3L.CETP) mice and (ii) whether the response of this model to different antidiabetic and hypolipidemic drugs is similar as in humans. METHODS: Male obese, IR and dyslipidemic E3L.CETP mice were treated with antidiabetic drugs rosiglitazone, liraglutide or an experimental 11β-hydroxysteroid-dehydrogenase-1 (HSD-1) inhibitor, or with hypolipidemic drugs atorvastatin, fenofibrate or niacin for 4-6 weeks. The effects on bw, IR and plasma and liver lipids were assessed. RESULTS:Rosiglitazone, liraglutide and HSD-1 inhibitor significantly decreased glucose and insulin levels or IR. Liraglutide and HSD-1 inhibitor also decreased bw. Atorvastatin, fenofibrate and niacin improved the dyslipidemia and fenofibrate and niacin increased high-density lipoprotein (HDL) cholesterol. In addition, hepatic triglycerides were significantly decreased by treatment with rosiglitazone and liraglutide, while hepatic cholesterol esters were significantly decreased by rosiglitazone and atorvastatin. CONCLUSIONS: We conclude that the E3L.CETP mouse is a promising novel translational model to investigate the effects of new drugs, alone or in combination, that affect IR, diabetic dyslipidemia and non-alcoholic fatty liver disease (NAFLD).
Authors: Brandon Ason; José W A van der Hoorn; Joyce Chan; Edward Lee; Elsbet J Pieterman; Kathy Khanh Nguyen; Mei Di; Susan Shetterly; Jie Tang; Wen-Chen Yeh; Margrit Schwarz; J Wouter Jukema; Rob Scott; Scott M Wasserman; Hans M G Princen; Simon Jackson Journal: J Lipid Res Date: 2014-09-25 Impact factor: 5.922
Authors: Wen Liang; Lars Verschuren; Petra Mulder; José W A van der Hoorn; Joanne Verheij; Andrea D van Dam; Mariette R Boon; Hans M G Princen; Louis M Havekes; Robert Kleemann; Anita M van den Hoek Journal: Br J Pharmacol Date: 2015-10-22 Impact factor: 8.739
Authors: Yared Paalvast; Albert Gerding; Yanan Wang; Vincent W Bloks; Theo H van Dijk; Rick Havinga; Ko Willems van Dijk; Patrick C N Rensen; Barbara M Bakker; Jan Albert Kuivenhoven; Albert K Groen Journal: Physiol Rep Date: 2017-10-16
Authors: Yvonne J W Rozendaal; Yanan Wang; Yared Paalvast; Lauren L Tambyrajah; Zhuang Li; Ko Willems van Dijk; Patrick C N Rensen; Jan A Kuivenhoven; Albert K Groen; Peter A J Hilbers; Natal A W van Riel Journal: PLoS Comput Biol Date: 2018-06-07 Impact factor: 4.475
Authors: Marius R Robciuc; Riikka Kivelä; Ian M Williams; Jan Freark de Boer; Theo H van Dijk; Harri Elamaa; Feven Tigistu-Sahle; Dmitry Molotkov; Veli-Matti Leppänen; Reijo Käkelä; Lauri Eklund; David H Wasserman; Albert K Groen; Kari Alitalo Journal: Cell Metab Date: 2016-04-12 Impact factor: 27.287
Authors: Wen Liang; Aswin L Menke; Ann Driessen; Ger H Koek; Jan H Lindeman; Reinout Stoop; Louis M Havekes; Robert Kleemann; Anita M van den Hoek Journal: PLoS One Date: 2014-12-23 Impact factor: 3.240
Authors: Andrea Jaeger; Lukas Zollinger; Christoph H Saely; Axel Muendlein; Ioannis Evangelakos; Dimitris Nasias; Nikoleta Charizopoulou; Jonathan D Schofield; Alaa Othman; Handrean Soran; Dimitris Kardassis; Heinz Drexel; Arnold von Eckardstein Journal: Sci Rep Date: 2018-09-24 Impact factor: 4.379